nye-FED-i-peen 
Unlabeled Use:
Absorption: Well absorbed after oral administration, but large amounts are rapidly metabolized (primarily by CYP3A4 enzyme system), resulting in ↓ bioavailability (45–70%); bioavailability is ↑ (80%) with extended-release forms.
Distribution: Unknown.
Protein Binding: 92–98%.
Metabolism/Excretion: Mostly metabolized by the liver.
Half-life: 2–5 hr.
Contraindicated in:
Use Cautiously in:
CV: ARRHYTHMIAS, HF, peripheral edema, bradycardia, chest pain, hypotension, palpitations, syncope, tachycardia.
Derm: STEVENS-JOHNSON SYNDROME, flushing, dermatitis, erythema multiforme, ↑ sweating, photosensitivity, pruritus/urticaria, rash.
EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus.
Endo: gynecomastia, hyperglycemia.
Neuro: headache, abnormal dreams, anxiety, confusion, dizziness, drowsiness, dysgeusia, jitteriness, nervousness, psychiatric disturbances, weakness.
GI: ↑liver enzymes, anorexia, constipation, diarrhea, dry mouth, dyspepsia, GI obstruction, nausea, ulcer, vomiting.
GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency.
Hemat: anemia, leukopenia, thrombocytopenia.
Metab: weight gain.
MS: joint stiffness, muscle cramps.
Neuro: paresthesia, tremor.
Resp: cough, dyspnea, shortness of breath.
Misc: gingival hyperplasia.
Drug-Drug:
Drug-Natural Products:
Drug-Food:
Adalat CC, Afeditab CR, Procardia, Procardia XL
Therapeutic Classification: antianginals, antihypertensives
Pharmacologic Classification: calcium channel blockers
NDC Code*